|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300074179 |
|
最近更新日期: Date of Last Refreshed on: |
2023-08-01 10:08:49 |
|
注册时间: Date of Registration: |
2023-08-01 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
针刺力敏腧穴治疗腹泻型肠易激综合征:随机对照试验 |
|
Public title: |
Acupuncture treatment based on sensitive points for Irritable bowel syndrome with diarrhea : a randomised controlled trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
针刺力敏腧穴治疗腹泻型肠易激综合征:随机对照试验 |
|
Scientific title: |
Acupuncture treatment based on sensitive points for Irritable bowel syndrome with diarrhea : a randomised controlled trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
黄蓉 |
研究负责人: |
姜凡 |
|
Applicant: |
Huang rong |
Study leader: |
Jiang fan |
|
申请注册联系人电话: Applicant telephone: |
+86 150 0791 4419 |
研究负责人电话:
Study leader's |
+86 173 4666 6303 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
r527712@163.com |
研究负责人电子邮件: Study leader's E-mail: |
jiangfanky@outlook.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江西省南昌市东湖区八一大道445号 |
研究负责人通讯地址: |
江西省南昌市东湖区八一大道445号 |
|
Applicant address: |
No. 445, Bayi Avenue, Donghu District, Nanchang, Jiangxi Province |
Study leader's address: |
No. 445, B445ayi Avenue, Donghu District, Nanchang, Jiangxi Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
江西中医药大学附属医院 |
||
|
Applicant's institution: |
Affiliated Hospital of Jiangxi University of Chinese Medicine |
||
|
研究负责人所在单位: |
江西中医药大学附属医院 |
||
|
Affiliation of the Leader: |
Affiliated Hospital of Jiangxi University of Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
JZFYLL20230628020 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
江西中医药大学附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the Affiliated Hospital of Jiangxi University of Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-06-28 00:00:00 | ||
|
伦理委员会联系人: |
熊明奕 |
||
|
Contact Name of the ethic committee: |
xiong ming yi |
||
|
伦理委员会联系地址: |
江西省南昌市东湖区八一大道445号 |
||
|
Contact Address of the ethic committee: |
No. 445, Bayi Avenue, Donghu District, Nanchang, Jiangxi Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 791 8636 1455 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
江西中医药大学附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Affiliated Hospital of Jiangxi University of Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江西省南昌市东湖区八一大道445号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 445, Bayi Avenue, Donghu District, Nanchang, Jiangxi Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
江西省自然科学基金(20224BAB216093) |
||||||||||||||||||||||
|
Source(s) of funding: |
Natural Science Foundation of Jiangxi Province (20224BAB216093) |
||||||||||||||||||||||
|
研究疾病: |
腹泻型肠易激综合征 |
||||||||||||||||||||||
|
Target disease: |
Irritable bowel syndrome with diarrhea |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
故本课题拟采用随机对照试验设计,通过临床招募IBS-D患者为研究对象,验证针刺力敏腧穴的有效性和安全性,进而探讨腧穴敏化程度高低与针刺疗效的优劣关系;并利用非靶向代谢组学技术,观察IBS-D患者的血清差异代谢物,探讨血清代谢物在IBS-D的作用及针刺力敏腧穴治疗IBS-D的效应机制。 |
||||||||||||||||||||||
|
Objectives of Study: |
The present study intends to adopt a randomized controlled trial design to verify the effectiveness and safety of acupuncture force-mining acupoints by clinically recruiting IBS-D patients as research subjects, and then to explore the relationship between the degree of sensitization of the acupoints and the advantages and disadvantages of the therapeutic efficacy of acupuncture. In addition, we will use non-targeted metabolomics technology to observe the serum differential metabolites of IBS-D patients, and to explore the roles of serum metabolites in IBS-D and the mechanism of the effect of acupuncture force-mining acupoints in the treatment of IBS-D. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)符合IBS-D诊断标准; (2)年龄在18-65岁; (3)基线期IBS-SSS总积分≥75分; (4)治疗前至少2周没有使用过任何治疗IBS的药物,近3个月未接受针对IBS-D的针灸治疗; (5)自愿参加研究,签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Meet IBS-D diagnostic criteria; (2) Age 18-65 years; (3) A total IBS-SSS score of ≥75 at baseline; (4) Had not used any medication for IBS for at least 2 weeks before treatment and had not received acupuncture for IBS-D in the last 3 months; (5) Voluntarily participated in the study by signing an informed consent form. |
||||||||||||||||||||||
|
排除标准: |
(1)有肠道器质性病变,或有影响消化道功能的全身疾病者; (2)合并有心血管系统、肝、肾、造血系统、精神疾病、认知功能明显障碍等严重原发性疾病者; (3)有腹部或直肠肛门手术史者; (4)妊娠、哺乳期、产后≤12个月妇女及过敏体质者; (5)金属过敏或严重惧针者; (6)正在参加其他临床试验,影响疗效指标观测者; (7)拒绝签署知情同意书,违反试验方案者。 注:有以上任何情况之一者,需排除。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Those with organic lesions of the intestinal tract, or systemic diseases that affect the function of the digestive tract; (2) Those who have a combination of serious primary diseases such as cardiovascular system, liver, kidney, hematopoietic system, psychiatric disorders, and significant cognitive dysfunction; (3) Those with a history of abdominal or rectal-anal surgery; (4) Pregnant, lactating, postpartum women ≤ 12 months and those with allergies; (5) Those with metal allergy or severe fear of needles; (6) Participating in other clinical trials, which will affect the observation of efficacy indicators; (7) Those who refuse to sign the informed consent and violate the trial program. Note: Anyone with any of the above conditions should be excluded. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-08-01 00:00:00至 To 2025-08-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-08-01 00:00:00 至 To 2025-07-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由不参与此次临床试验的统计人员使用SPSS 25.0统计软件生成随机数。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Random numbers were generated by a statistician who was not involved in this clinical trial using SPSS 25.0 statistical software. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
试验采用盲法,对患者、针刺操作医师、数据采集人员、数据统计人员等进行设盲。 |
|
Blinding: |
The trial was blinded to the patient, the acupuncture operator, the data collector, and the data statistician. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
江西中医药大学附属医院 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Affiliated Hospital of Jiangxi University of Chinese Medicine |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表和专人收集整理数据。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF and a dedicated person collects and organizes the data. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |